​​​​

CELLTIUM envisions a future where people with CMT1A and related rare neurological disorders have access to disease-modifying therapies.

 ​​

The Challenge

Patients with CMT1A and related inherited peripheral neuropathies have no approved disease-modifying treatment options. Advancing new therapies requires a more predictive, biologically grounded approach to drug discovery.

​

​How We Aim to Change It

CELLTIUM is building a precision neurotherapeutics company that integrates disease biology, quantitative phenotyping, and AI/ML-driven analytics from the earliest stages of discovery. We translate complex neurobiology into differentiated therapeutic candidates designed to address core disease mechanisms and deliver meaningful clinical benefit.

​

​Our Approach

Our work begins with predictive cellular and in vivo models designed to capture the core biology of rare neurological disorders. Built on this foundation, our proprietary PRECISION™ platform accelerates target discovery, candidate prioritization, and lead optimization.

​

​Our Commitment

CELLTIUM holds its science to the highest standards, combining scientific rigor with the urgency patients and families deserve.

​